FDA Approves Ingrezza for Tardive Dyskinesia Treatment

Understanding Dyskinesia and Tardive Dyskinesia

Dyskinesia refers to a disorder that leads to involuntary and uncontrollable movements of the body. Tardive dyskinesia (TD), a specific form of dyskinesia, is a rare neurological condition marked by involuntary facial and jaw movements. Common symptoms in patients include repetitive facial actions such as grimacing, lip-smacking, and tongue protrusion. In some instances, individuals may also experience involuntary movements in their limbs or trunk.

TD typically arises in patients who have a prolonged history of antipsychotic medication use for conditions such as schizophrenia, depression, or bipolar disorder. This condition can exacerbate the stigma surrounding mental health issues. While reducing the dosage of antipsychotic medications may alleviate some symptoms, there is currently no definitive cure for TD.

Ingrezza: A Breakthrough Treatment

The FDA has recently granted approval for Ingrezza (valbenazine), marking it as the first medication specifically designed to treat TD. Developed by Neurocrine Biosciences Inc., Ingrezza capsules selectively inhibit the vesicular monoamine transporter 2 (VMAT2), a protein crucial for regulating dopamine release. By reducing dopamine levels in brain areas responsible for motor control, Ingrezza aims to mitigate the involuntary movements associated with TD.

Clinical Trial Success

Ingrezza’s FDA approval is supported by positive outcomes from multiple clinical trials. Notably, a Phase 3 trial involving 234 adult participants with pre-existing mental health conditions demonstrated that those administered Ingrezza once daily experienced significant improvements in involuntary movement severity after six weeks compared to those receiving a placebo. The drug was generally well tolerated, with no observed worsening of depression, suicidal thoughts, or related behaviors among participants.

Implications for Tardive Dyskinesia Patients

The approval of Ingrezza represents a significant advancement in the management of TD, offering hope for patients grappling with the often enduring and irreversible side effects of long-term antipsychotic medication use.

Written By: Fiona Wong, PhD